GS 9901

Drug Profile

GS 9901

Alternative Names: GS-9901

Latest Information Update: 16 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Lymphoma

Most Recent Events

  • 01 Dec 2014 Phase-I clinical trials in Chronic lymphocytic leukaemia and Lymphoma (Second-line therapy or greater, Refractory metastatic disease) in USA (PO) (NCT02258555)
  • 08 Oct 2014 Preclinical trials in Chronic lymphocytic leukaemia in USA (PO) prior to October 2014
  • 08 Oct 2014 Preclinical trials in Follicular lymphoma in USA (PO) prior to October 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top